29 Dec 2017 09:00
29 December 2017
 Clinigen Group plc
("Clinigen" or the "Group")
Total Voting Rights and Capital
In conformity with Rule 5.6.1 of the Disclosure Guidance and Transparency Rules, the Group notifies the market that as at 29 December 2017 Clinigen's issued share capital consists of 122,286,083 ordinary shares of 0.1 pence each with voting rights. No shares are held in Treasury.
Â
The above figure of 122,286,083 may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the FCA's Disclosure Guidance and Transparency Rules.
Â
-Ends-
Â
Contact details
Â
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Matt Parrish, Head of Investor Relations | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
Â
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
Â
For more information, please visit www.clinigengroup.comÂ
Â